OncoMatch/Clinical Trials/NCT03899155
Pan Tumor Rollover Study
Official title: Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
Is NCT03899155 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments for cancer.
Treatment: Nivolumab · Ipilimumab · Cabozantinib · Trametinib · Relatlimab · Nivolumab + Relatlimab · Capecitabine · Bevacizumab · Temozolomide · Rucaparib · Daratumumab · Regorafinib · Leucovorin · Fluorouracil · Oxaliplatin · Enzalutamide · Sunitinib · Pemetrexed · Pembrolizumab — Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Tumor Agnostic
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0220 · Huntsville, Alabama
- University of Arizona College of Medicine · Tucson, Arizona
- Innovative Clinical Research Institute · Lynwood, California
- Local Institution · San Francisco, California
- Local Institution - 0099 · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03899155 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify